2023 - Research.com Best Female Scientist Award
2022 - Research.com Best Female Scientist Award
Many of her studies involve connections with topics such as Adverse effect and Internal medicine. In her study, she carries out multidisciplinary Oncology and Cancer research research. She performs multidisciplinary studies into Cancer research and Oncology in her work. Julie M. Vose conducted interdisciplinary study in her works that combined Immunology and Immune system. Immune system is frequently linked to Peripheral T-cell lymphoma in her study. She merges Peripheral T-cell lymphoma with T cell in her study. In her works, Julie M. Vose conducts interdisciplinary research on T cell and Immunology. In her study, she carries out multidisciplinary Chemotherapy and Neutropenia research. She performs multidisciplinary study in Diffuse large B-cell lymphoma and International Prognostic Index in her work.
Internal medicine is often connected to Neutropenia in her work. In her study, she carries out multidisciplinary Oncology and Cancer research research. Julie M. Vose performs integrative study on Cancer research and Oncology. Julie M. Vose undertakes interdisciplinary study in the fields of Chemotherapy and Rituximab through her research. In her works, Julie M. Vose undertakes multidisciplinary study on Gastroenterology and Internal medicine. By researching both Immunology and Antibody, Julie M. Vose produces research that crosses academic boundaries. Julie M. Vose brings together Surgery and Chemotherapy to produce work in her papers. Her Transplantation study frequently draws parallels with other fields, such as Hematopoietic stem cell transplantation. Her study brings together the fields of Transplantation and Hematopoietic stem cell transplantation.
Julie M. Vose regularly ties together related areas like Chimeric antigen receptor in her Internal medicine studies. In her research, she undertakes multidisciplinary study on Lymphoma and Mantle cell lymphoma. She integrates many fields in her works, including Oncology and Gastroenterology. She performs multidisciplinary study in the fields of Gastroenterology and Oncology via her papers. Her study deals with a combination of Immunology and Pathology. Julie M. Vose undertakes multidisciplinary studies into Pathology and Immunology in her work. In her articles, she combines various disciplines, including Cancer research and Genetics. Julie M. Vose conducts interdisciplinary study in the fields of Genetics and Cancer research through her works. Her study in Astrobiology extends to Refractory (planetary science) with its themes.
In her study, Julie M. Vose carries out multidisciplinary Lymphoma and Targeted therapy research. She merges Targeted therapy with Lymphoma in her study. Internal medicine and Intensive care medicine are two areas of study in which she engages in interdisciplinary research. Intensive care medicine and Internal medicine are two areas of study in which Julie M. Vose engages in interdisciplinary work. Her Oncology study frequently involves adjacent topics like Chemotherapy regimen. The study of Chemotherapy regimen is intertwined with the study of Oncology in a number of ways. Cancer research and Leukemia are two areas of study in which she engages in interdisciplinary work. Her work blends Leukemia and Cancer research studies together. Her Immunology study frequently involves adjacent topics like Diffuse large B-cell lymphoma.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Revised response criteria for malignant lymphoma
Bruce D. Cheson;Beate Pfistner;Malik E. Juweid;Randy D. Gascoyne.
Journal of Clinical Oncology (2007)
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
Andreas Rosenwald;George Wright;Wing C. Chan;Wing C. Chan;Joseph M. Connors.
The New England Journal of Medicine (2002)
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
B D Cheson;S J Horning;B Coiffier;M A Shipp.
Journal of Clinical Oncology (1999)
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Julie M. Vose;M. Neumann;Mildred E. Harris.
Journal of Clinical Oncology (2008)
Stromal gene signatures in large-B-cell lymphomas
G Lenz;G Wright;S S Dave;W Xiao.
The New England Journal of Medicine (2008)
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave;George Wright;Bruce Tan;Andreas Rosenwald;Andreas Rosenwald.
The New England Journal of Medicine (2004)
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Andreas Rosenwald;George Wright;Karen Leroy;Xin-You Yu.
Journal of Experimental Medicine (2003)
ALK - anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project
Kerry J. Savage;Nancy Lee Harris;Julie Marie Vose;Fred Ullrich.
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
Andreas Rosenwald;George Wright;Adrian Wiestner;Wing C. Chan;Wing C. Chan.
Cancer Cell (2003)
Molecular diagnosis of Burkitt's lymphoma.
Sandeep S. Dave;Kai Fu;George W. Wright;Lloyd T. Lam.
The New England Journal of Medicine (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: